Amyris, a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market technology platform announced that it has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris' ingredients.

The transaction is subject to antitrust review under the Hart-Scott-Rodino Act (HSR) with a standard waiting period of thirty days. Accordingly, the transaction is expected to sign and close early in the first quarter of 2023. Both parties have agreed to confidentiality regarding further details about the transaction during this period.

The transaction, with an expected value of over $500 million, is expected to follow a structure similar to those completed by Amyris in 2021, and include an exclusive worldwide license for the distribution, marketing and selling of two Amyris ingredients. Amyris would continue to develop, scale and manufacture the ingredients. In addition, the parties are expected to enter a long-term R&D collaboration partnership for the development of new molecules.

"We are pleased with the strong continued growth across our core business. The power of our technology is evident, and we are very excited about the potential of this new partnership and the continued growth of the two ingredients," commented John Melo, President and Chief Executive Officer. "This is our third transaction of this nature and what we believe to be a strategic part of our business model for the value creation of our technology."